Birdwatch Note
2024-04-11 03:37:56 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
多数回接種で感染すると命の危機との噂ですが実際には例えば2価ワクチンの接種の有効性は二価ワクチンの未接種者や全ワクチン未接種者と比べたコントロールされた観察研究のメタ解析でも確認され↓ https://www.frontiersin.org/articles/10.3389/fmed.2023.1322396/full https://www.medrxiv.org/content/10.1101/2024.01.10.24301107v1 国内でも完全未接種者と比べた二価ワクチンの有効性↓もXBBワクチンの有効性↓↓も報告され https://www3.nhk.or.jp/news/html/20230304/k10013998631000.html https://www.tm.nagasaki-u.ac.jp/versus/results/20240228.pdf XBBワクチンの死亡に関してもデンマークで入院予防効果がこの研究では確認されXBBワクチン接種群では1人(100リスク保持人・年当たり0-008人)XBBワクチン未接種群では23人(同0-066人)がCOVID-19入院から2週間以内に死亡となっています https://www.thelancet.com/action/showPdf?pii=S1473-3099%2823%2900746-6
Written by F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1778240117037248831
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1778266203678704002
- noteId - 1778266203678704002
- participantId -
- noteAuthorParticipantId - F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D Participant Details
- createdAtMillis - 1712806676203
- tweetId - 1778240117037248831
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 1
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- 多数回接種で感染すると命の危機との噂ですが実際には例えば2価ワクチンの接種の有効性は二価ワクチンの未接種者や全ワクチン未接種者と比べたコントロールされた観察研究のメタ解析でも確認され↓ https://www.frontiersin.org/articles/10.3389/fmed.2023.1322396/full https://www.medrxiv.org/content/10.1101/2024.01.10.24301107v1 国内でも完全未接種者と比べた二価ワクチンの有効性↓もXBBワクチンの有効性↓↓も報告され https://www3.nhk.or.jp/news/html/20230304/k10013998631000.html https://www.tm.nagasaki-u.ac.jp/versus/results/20240228.pdf XBBワクチンの死亡に関してもデンマークで入院予防効果がこの研究では確認されXBBワクチン接種群では1人(100リスク保持人・年当たり0-008人)XBBワクチン未接種群では23人(同0-066人)がCOVID-19入院から2週間以内に死亡となっています https://www.thelancet.com/action/showPdf?pii=S1473-3099%2823%2900746-6
Note Status History
createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
2024-04-11 03:37:56 UTC (1712806676203) |
2024-04-11 09:38:07 UTC (1712828287388) |
CURRENTLY_RATED_HELPFUL | 2024-04-12 11:24:43 UTC (1712921083732) |
CURRENTLY_RATED_HELPFUL | 2024-04-11 09:38:07 UTC (1712828287388) |
CURRENTLY_RATED_HELPFUL |
Note Ratings
rated at | rated by | |
2024-04-11 11:28:49 -0500 | Rating Details | |
2024-04-11 08:36:42 -0500 | Rating Details | |
2024-04-11 07:09:39 -0500 | Rating Details | |
2024-04-11 06:44:44 -0500 | Rating Details | |
2024-04-11 02:55:48 -0500 | Rating Details | |
2024-04-11 01:59:25 -0500 | Rating Details | |
2024-04-11 01:12:57 -0500 | Rating Details | |
2024-04-11 00:52:15 -0500 | Rating Details | |
2024-04-11 00:39:29 -0500 | Rating Details | |
2024-04-11 00:34:30 -0500 | Rating Details | |
2024-04-11 00:34:01 -0500 | Rating Details | |
2024-04-11 00:08:56 -0500 | Rating Details | |
2024-04-10 23:49:03 -0500 | Rating Details | |
2024-04-10 23:36:28 -0500 | Rating Details | |
2024-04-10 23:35:04 -0500 | Rating Details | |
2024-04-10 23:25:55 -0500 | Rating Details | |
2024-04-10 23:16:04 -0500 | Rating Details | |
2024-04-10 23:10:35 -0500 | Rating Details | |
2024-04-10 23:00:49 -0500 | Rating Details | |
2024-04-10 23:00:31 -0500 | Rating Details | |
2024-04-10 22:59:41 -0500 | Rating Details | |
2024-04-10 22:58:55 -0500 | Rating Details | |
2024-04-10 22:53:34 -0500 | Rating Details | |
2024-04-10 22:52:45 -0500 | Rating Details | |
2024-04-10 22:51:49 -0500 | Rating Details | |
2024-04-10 22:50:36 -0500 | Rating Details | |
2024-04-10 22:49:36 -0500 | Rating Details | |
2024-04-10 22:49:30 -0500 | Rating Details | |
2024-04-10 22:47:32 -0500 | Rating Details | |
2024-04-15 05:10:56 -0500 | Rating Details | |
2024-04-13 17:05:25 -0500 | Rating Details | |
2024-04-11 22:09:11 -0500 | Rating Details | |
2024-04-11 06:31:25 -0500 | Rating Details | |
2024-04-11 04:40:57 -0500 | Rating Details | |
2024-04-11 04:38:32 -0500 | Rating Details | |
2024-04-11 04:26:51 -0500 | Rating Details | |
2024-04-11 03:17:21 -0500 | Rating Details | |
2024-04-11 02:08:12 -0500 | Rating Details | |
2024-04-11 01:24:53 -0500 | Rating Details | |
2024-04-11 01:24:52 -0500 | Rating Details | |
2024-04-11 00:40:09 -0500 | Rating Details | |
2024-04-11 00:30:10 -0500 | Rating Details | |
2024-04-10 23:56:47 -0500 | Rating Details | |
2024-04-10 23:56:44 -0500 | Rating Details | |
2024-04-10 23:39:35 -0500 | Rating Details | |
2024-04-10 23:27:49 -0500 | Rating Details | |
2024-04-10 23:22:22 -0500 | Rating Details | |
2024-04-10 23:02:42 -0500 | Rating Details | |
2024-04-10 22:57:17 -0500 | Rating Details | |
2024-04-10 22:56:06 -0500 | Rating Details | |
2024-04-10 22:53:20 -0500 | Rating Details | |
2024-04-10 22:53:17 -0500 | Rating Details | |
2024-04-10 22:52:29 -0500 | Rating Details | |
2024-04-10 22:51:23 -0500 | Rating Details | |
2024-04-10 22:47:27 -0500 | Rating Details | |
2024-04-10 22:46:43 -0500 | Rating Details | |
2024-04-10 22:46:04 -0500 | Rating Details | |
2024-04-10 22:44:25 -0500 | Rating Details | |
2024-04-16 02:24:59 -0500 | Rating Details | |
2024-04-13 09:32:44 -0500 | Rating Details | |
2024-04-12 15:30:22 -0500 | Rating Details | |
2024-04-11 14:06:02 -0500 | Rating Details | |
2024-04-11 10:45:00 -0500 | Rating Details | |
2024-04-11 05:38:31 -0500 | Rating Details | |
2024-04-11 05:06:14 -0500 | Rating Details | |
2024-04-11 04:39:22 -0500 | Rating Details | |
2024-04-11 03:44:05 -0500 | Rating Details | |
2024-04-11 02:49:23 -0500 | Rating Details | |
2024-04-11 02:31:00 -0500 | Rating Details | |
2024-04-11 01:58:02 -0500 | Rating Details | |
2024-04-11 01:21:03 -0500 | Rating Details | |
2024-04-11 01:12:17 -0500 | Rating Details | |
2024-04-11 01:06:23 -0500 | Rating Details | |
2024-04-11 00:54:14 -0500 | Rating Details | |
2024-04-11 00:41:27 -0500 | Rating Details | |
2024-04-11 00:40:38 -0500 | Rating Details | |
2024-04-11 00:20:44 -0500 | Rating Details | |
2024-04-11 00:12:24 -0500 | Rating Details | |
2024-04-11 00:08:02 -0500 | Rating Details | |
2024-04-10 23:58:33 -0500 | Rating Details | |
2024-04-10 23:51:34 -0500 | Rating Details | |
2024-04-10 23:47:46 -0500 | Rating Details | |
2024-04-10 23:42:06 -0500 | Rating Details | |
2024-04-10 23:25:15 -0500 | Rating Details | |
2024-04-10 23:16:04 -0500 | Rating Details | |
2024-04-10 23:15:45 -0500 | Rating Details | |
2024-04-10 23:13:17 -0500 | Rating Details | |
2024-04-10 22:59:02 -0500 | Rating Details | |
2024-04-10 22:57:32 -0500 | Rating Details | |
2024-04-10 22:53:23 -0500 | Rating Details | |
2024-04-10 22:51:45 -0500 | Rating Details | |
2024-04-10 22:49:12 -0500 | Rating Details | |
2024-04-10 22:45:55 -0500 | Rating Details | |
2024-04-10 22:45:48 -0500 | Rating Details |